Clinical Trials on HER2+ Early or Locally Advanced Breast Cancer in New Zealand
Total 464 results
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...United States
-
Hoffmann-La RocheCompletedHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast CancerIndia
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
R-PharmGlaxoSmithKlineTerminatedLocally Advanced or Metastatic Breast CancerUnited States, Italy, Australia
-
Hoffmann-La RocheCompleted
-
Alison StopeckRecruitingBreast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | TNBC, Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Neoadjuvant ChemotherapyUnited States
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
Memorial Sloan Kettering Cancer CenterNovartis PharmaceuticalsCompletedMetastatic or Locally-advanced Unresectable Breast CancerUnited States
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKlineCompletedHER2-Positive Early Stage Breast CancerUnited States
-
Sermonix Pharmaceuticals Inc.Linical Accelovance GroupActive, not recruitingLocally Advanced or Metastatic Breast CancerUnited States, Canada, Israel
-
AstraZenecaRecruitingLocally Advanced (Inoperable) or Metastatic Breast CancerSpain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Brazil, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Poland, Sweden, Italy
-
Icahn School of Medicine at Mount SinaiTerminatedLocally Advanced Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
OncoTherapy Science, Inc.RecruitingRelapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2/Neu-positive Breast CancerUnited States
-
Hoffmann-La RocheRecruitingInoperable, Locally Advanced or Metastatic, ER-positive Breast CancerUnited States, Korea, Republic of, Spain, Australia, Israel
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
-
Dartmouth-Hitchcock Medical CenterTerminatedLocally Advanced Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Locally Advanced Breast CancerUnited States
-
Hoffmann-La RocheRecruitingLocally Advanced or Metastatic Breast CancerFrance, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
SCRI Development Innovations, LLCDaiichi Sankyo, Inc.RecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerUnited States
-
AstraZenecaCompletedER+ HER2- Advanced Breast CancerUnited States, United Kingdom, Korea, Republic of
-
Columbia UniversityCompletedBreast Cancer | Locally Advanced Malignant NeoplasmUnited States
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
West German Study GroupAstraZenecaNot yet recruitingHER2-positive Early Breast CancerGermany
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
AstraZenecaActive, not recruitingLocally Advanced (Inoperable) or Metastatic Breast CancerUnited States, Italy, Spain, Belgium, Hungary, Poland, Canada, France, Germany, Korea, Republic of, Japan, Peru, Russian Federation, United Kingdom, China, Taiwan, Israel, Australia, Argentina
-
Alison StopeckEli Lilly and Company; AstraZenecaWithdrawnLocally Advanced Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer FemaleUnited States
-
Puma Biotechnology, Inc.CompletedEarly Stage HER2+ Breast CancerSpain, United States, France, Australia, Germany, Austria, Canada
-
Taiho Oncology, Inc.TerminatedAdvanced Solid Tumors With HER2 Abnormalities | Advanced Solid Tumors With HER3 AbnormalitiesUnited States, Spain, France, United Kingdom
-
Relay Therapeutics, Inc.Active, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA MutationUnited States
-
Eli Lilly and CompanyGenentech, Inc.CompletedMetastatic Breast Cancer | Locally Advanced Breast CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States, South Africa
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)RecruitingHER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of BreastUnited States
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedHR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerCanada
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
AstraZenecaCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerSweden, United States, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Canada, Belgium, Denmark, Israel, Argentina, France, Brazil, Spain
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...